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Basic Research and Clinical 
Examination of Tumor Virus
Tatsuaki Tsuruyama, Shuichiro Ogawa and Norishige Yamada
Abstract
Tumor viruses cause cancer; thus, extensive studies are being conducted on 
them. In this article, we will review the basic medical research on the current clini-
cal genetic tests for tumor viruses such as human papilloma virus, hepatitis B virus, 
and T-cell leukemia virus. Recently, clinical genetic tests have been developed for 
quick diagnosis of the tumor virus infection. Additionally, we will review the muta-
genesis of murine leukemia retrovirus. In particular, we will focus on the insertional 
mutagenesis. This will help in deciding the direction of future virus research by 
combining clinical and basic research.
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1. Introduction
1.1 History of tumor virus research
Tumor virus research is an important subject to understand the molecular 
biology of tumor viruses and carcinogenesis. Dr. Katsusaburo Yamagiwa, a Japanese 
pathologist, is famous for the experiment in which coal tar was applied to rabbit 
ears to induce carcinogenesis in 1915. He was also a candidate for the Nobel Prize 
in Medicine. The following year, his student Dr. Akira Fujinami was appointed to 
study carcinogenesis in Germany for 4 years. After returning to Japan, in 1900, 
he became the first professor at the Department of Pathology, Kyoto Imperial 
University Medical College. In 1905, he started studying chicken tumors, and as 
early as 1910, he established a chicken breast tumor transplant system. He had 
suggested the possibility of carcinogenesis by filterable pathogens, which were later 
called Fujinami sarcoma virus (FSV). He is also well known for the discovery of 
Japan schistosomiasis.
Interestingly, in the same year, Peyton Rous, who was studying at the Rockefeller 
laboratory in the United States, also established the avian sarcoma transplant 
system. In 1966, Rous received the Nobel Prize in Physiology and Medicine for the 
discovery of carcinogenic viruses. Hanafusa et al. elucidated the FSV gene structure 
and identified the similarity with the Rous sarcoma virus gene structure [1]. Both 
FSV and Rous sarcoma virus belong to the same alpha-retrovirus. FSV has the onco-
gene v-fps in its genome [2]. It also has long terminal repeats (LTRs) at the ends of 
the genome that stabilizes as parts of the host cell genome when inserted into host 
mesenchymal cells after reverse transcription. In addition to the host cell division, 
the viral genome also replicates during the DNA replication cycle. Tyrosine-protein 
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kinase transforming protein Fps encoded by v-fps has the ability to induce trans-
formation by promoting tyrosine phosphorylation of the PDGFbeta receptor [3, 4]. 
Thus, the Japanese scientists have greatly contributed to the field during the early 
days of oncology research.
1.2 Viral genome integration
Retroviral integration is a type of insertional mutagenesis. Integration pro-
cesses are widely studied from biochemistry, and their molecular mechanisms are 
elucidated. Retrovirus-induced tumorigenesis is divided into two types. First, the 
retroviral genome carries the oncogene such as v-onc, and the inserted viral element 
may induce malignant tumors. Second, the inserted retroviral element has the 
promoter or enhancer activity of the host proto-oncogene. The genome of human 
papilloma virus (HPV), hepatitis B virus (HBV), human T-cell adult leukemia 
virus (HTLV) [5], avian sarcoma virus (ASV) [6], feline leukemia virus (FeLV) [7], 
murine leukemia virus (MLV) [8–13], and mouse mammary tumor virus (MMTV) 
can be integrated in the host genome. As a survival strategy, the inserted retroviral 
genome (provirus) is thereafter replicated during host cell division.
The retroviral promoter and enhancer elements in LTRs originally promote the 
expression of retroviral genes such as gag, env, and pol [14] (Figure 1). However, 
once integrated in the host genome, LTR elements can promote host gene expres-
sion in place of the host genome promoters and enhancers. After infection, the 
retroviral RNA genome is reverse-transcribed into DNA, which forms a pre-inser-
tion complex (PIC) with the oligomeric integrase enzyme [15], which catalyzes 
the insertion reaction. The PIC crosses the nuclear envelope through the nuclear 
pore complex to access host cell DNA. The retroviral DNA ends then attack and 
nick the host DNA with target nucleotides. These ends are ligated to the truncated 
host DNA to complete the insertion process involving replication of the target 
nucleotides.
To date, extensive research has been conducted on target motifs for retroviral 
insertion to better understand tumorigenesis, neuronal damage, aging, and immu-
nodeficiency including acquired immunodeficiency syndrome (AIDS). Retroviral-
host DNA interactions support specific host DNA structures [16–21] but are less 
likely to be inserted into particular base sequences. Previous studies on human 
immunodeficiency virus (HIV)-1 insertion have shown that the insertion sites are 
distributed in 10-bp cycles on the nucleosome surface of the outward DNA major 
groove of chromatin [16, 22].
Figure 1. 
A common structure of the retroviral genome. Plus strand RNA is shown. R, terminal redundant sequence; U5, 
unique 5′ sequence; PBS, tRNA primer-binding site; gag, group-specific antigen encoding capsid protein MA 
(matrix), CA, capsid protein; NC, nucleocapsid; pro, protease; pol, polymerase including reverse transcriptase 
(RT) and integrase (IN) catalyzing integration; env, envelope glycoproteins; U3, unique 3′ sequence. U3, R, 
and U5 are duplicated at both ends of the DNA provirus genome in the host genome sequence to form the long 
terminal repeat (LTR). LTR is essential for the initiation of viral DNA syntheses by reverse transcription as 
well as the integration of proviral DNA and the regulation of viral gene expression.
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2. HPV
HPV is one of the most common viruses that infect more than half women 
once in life through sexual intercourse. It is a small DNA virus with approximately 
8000 bp circular double-stranded DNA in its genome. The viral particle has icosa-
hedral capsid structure as its outer shell. The virus has been known to be involved in 
the development of cervical, anal, and vaginal cancer and condyloma acuminatum. 
Many types of HPV are known, and high-risk HPV based on this cancer risk is 
concentrated in specific subgroups epidemiologically. In particular, types 16 and 18 
have high carcinogenic risks of cervical intraepithelial neoplasia (CIN) and cancer. 
Type 16 has been detected in the Japanese 5-year-old girls [23]. High-risk group 
(types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) causes bladder cancer and 
pharyngeal cancer in addition to vulvar and cervical cancer. Low-risk group (HPV2, 
27, and 57) causes verruca vulgaris that develops in the hands and feet [24].
HPV genome has early genes (E1, E2, E4, E5, E6, and E7) and late genes encod-
ing viral capsid proteins (L1 and L2). E6 and E7 are considered to be involved in 
carcinogenesis. E6 binds to a tumor-suppressor gene product p53 and degrades 
p53 through promoting the ubiquitination. It also contributes to carcinogenesis by 
reactivating telomerase reverse transcriptase (hTERT) and degrading proteins with 
PDZ domain [shared by—post-synaptic density protein (PSD95), Drosophila disc 
large tumor suppressor (Dlg1), and Zonula occludens-1 protein (zo-1)]. E7 binds to 
the tumor suppressor gene pRb and contributes to carcinogenesis by releasing and 
activating the transcription factor E2F bound to pRb. It is also involved in carcino-
genesis by interacting with cyclin-dependent kinase (Cdk) inhibitors p21 and p27 
to evade cell cycle checkpoint mechanisms and apoptosis. However, in many cases, 
immortalization does not occur only by the actions of human cervix mucosal cells 
E6 and E7. In the well-known HeLa cell line, telomerase is activated, preventing the 
gradual shortening of telomeres in cell death.
High-risk HPV can be detected in more than 90% patients suffering from 
cervical cancer and dysplasia, which is a precancerous lesion, and in the vulva of 
5% normal women. Although HPV is also integrated into the genome of host cells, 
its integration pattern has unique features. The E6 and E7 genes are retained in the 
provirus with frequent deletion mutations in E2 gene. Thus, the viral genome is also 
found to be truncated in the complex reaction of integration, but its carcinogenicity 
is rather enhanced. Low-grade dysplasia of the cervix and cervical intraepithelial 
neoplasia (CIN) is well known. These pathological changes are reversible and are 
known to spontaneously disappear within about 3 years. However, about 10% 
infected patients sustain the infection for more than 3 years, and cervical cancer 
occurs after several months to several decades in some of them. HPV genome is 
integrated into the host cell genome during the progression of CIN, and the pro-
gression becomes irreversible.
2.1 Clinical test for HPV detection
HPV-DNA typing tests have been conducted using real-time PCR, loop-
mediated isothermal amplification (LAMP) [25, 26], invader, and hybridization 
methods. In recent years, the Clinichip method [27] combining LAMP is broadly 
available in advanced countries including Japan due to the ability to amplify genes 
at a constant temperature. The LAMP method is very specific because it uses four 
primers to recognize the six regions of the HPV genome. Nonspecific amplification 
does not occur because the amplification reaction depends on the order of the six 
regions of the HPV gene. In addition, since the amplification product constitutes 
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the target gene sequence, the target gene can be detected immediately by the pres-
ence or absence of amplification.
In an environment where electricity availability is limited, easy-to-use and dura-
ble reagents and equipment are desirable. In recent years, attempts have been made 
to spread virus testing as point-of-care tests (POCT) [28]. For some pathogens such 
as malarial parasite (Plasmodium), HIV, Ebola virus, and Zika virus, development of 
the testing system by fluid device is in progress; however, HPV detection methods 
have not been put to practical use as POCT yet.
3. HBV
HBV has been identified as the pathogen that causes acute and chronic hepatitis 
B [29, 30]. HBV is a DNA hepatitis virus and has a double structure of an envelope 
and a core. In persistent infections, the HBV genome is often inserted into the 
hepatocyte genome and is not eliminated by the host’s immune system. Several 
studies on many common insertion sites have identified common integration sites 
in the HBV genome by full genome sequence of hepatocellular carcinoma [31]. The 
envelope protein of HBV covers the HBs antigen, and the core protein is called the 
HBc antigen. HBV DNA encodes HBs antigen, HBc antigen, X protein, and DNA 
polymerase. The HBe antigen is translated from the pre-C gene and the down-
stream HBc antigen. It is released into blood as a soluble protein during HBV virus 
growth and therefore considered a marker for the virus growth. In asymptomatic 
carriers positive for HBe antigen, the host immune system continuously reacts 
with HBV-infected hepatocytes, and biopsy reports show persistent lymphocyte 
infiltration in the portal vascular area of liver tissues. If the damage persists for a 
long time, remodeling of the hepatocytes occurs and progresses to cirrhosis with 
obvious fibrotic crosslinks. After all, when seroconversion occurs in HBV carri-
ers negative for HBe antigen and positive for HBe antibody, the patient becomes 
an inactive carrier. HBV particles remain alive during periods of inactivity. Host 
immune system can attack infected hepatocytes, and hepatocyte regeneration may 
occur with genomic mutations, and the effects of the inserted HBV genome persist. 
Hepatocellular carcinoma can develop with persistent liver dysfunction associated 
with liver cirrhosis.
3.1 Clinical test for HBV detection
For the diagnosis of hepatitis B, HBs antigen/antibody, HBc antibody, HBe 
antigen/antibody, and HBV DNA are detected, and HBV DNA polymerase activity 
is measured. HBs antigen is produced continuously in patients with HBV infec-
tion; thus, positive results for HBe antigen can diagnose current infection with 
HBV. Recently, the HBs antigen measurement system has become very sensitive, 
and infected people have been found to be positive for HBs. In addition to antigen or 
antibody detection method, viral DNA detection system (quantitative PCR, LAMP 
method) has been used for clinical tests. Liver fibrosis is seen as a precancerous 
stage of HBV and hepatitis C virus (HCV) infection. Liver biopsy and qualita-
tive analysis of hyaluronic acid and type IV collagen in blood are well-known 
methods to evaluate liver fibrosis progress. Monitoring of glycolysis of serum 
M2BP (Macingo binding biomarker) is used to evaluate liver fibrotic stage [32]. 
Recent studies have suggested that the most common cause of nonexclusion of 
HBV is covalently closed circular DNA (cccDNA). When HBV infects hepatocytes, 
the incomplete duplex circular DNA genome becomes a complete duplex and is 
retained in the nucleus in the form of cccDNA. This HBV gene is the source of HBV 
5Basic Research and Clinical Examination of Tumor Virus
DOI: http://dx.doi.org/10.5772/intechopen.89331
replication. Since cccDNA is an extremely stable biochemical structure, it can be 
used as a monitoring marker after the infection. As the nucleic acid analog drug has 
little effect on reducing HBV cccDNA, a high risk of reactivation remains. If host 
immunity is suppressed, the reactivation occurs from this cccDNA as a starting 
transcriptional point. Therefore, elimination or suppression of reactivation will be 
central to future therapeutic strategies [33].
In the clinical tests for HBV detection, the detection sensitivity of the enzyme-
linked immunosorbent assay (ELISA) method for HBs antigen is higher than those 
of other tests. Each available method depends on the titer of the used antibody, and 
the sensitivity varies. In particular, the mutation in the gene encoding the envelope 
protein HBs antigen may cause false negative results. Many test kits increase sen-
sitivity by using multiple monoclonal antibodies or a polyclonal antibody that has 
an affinity for multiple epitopes. In some cases, antibodies that recognize epitopes 
within the viral particle are used instead of surface proteins with many mutations. 
However, the high sensitivity of many kits may instead cause false positive results. 
Accordingly, actual early diagnosis requires careful evaluation of test results in 
combination with other clinical tests.
4. HTLV type 1 (HTLV-1)
Another important human carcinogenic virus is human T-cell leukemia virus 
type 1 (HTLV-1). This virus has the potential to cause adult T-cell leukemia/lym-
phoma (ATL), HTLV-1-associated myelopathy (HAM), and HTLV-1 uveitis (HU). 
These diseases develop in HTLV-1 carriers after prolonged latent infection. HTLV-1 
carriers are particularly prevalent in southwest Japan, including Kyushu, Shikoku, 
and Okinawa. HTLV-1 was isolated and reported by Gallo R as the first human 
pathogenic retrovirus in 1980. Yorio Hinuma of Kyoto University in Japan precisely 
analyzed the genomic structure and identified the HTLV-1 [34]. HTLV-1 is a weakly 
infective virus particle, and cell-to-cell transmission is the main route of infection.
4.1 Molecular biology of HTLV-1
ATL is a hematologic malignancy in which abnormal lymphocytes appear 
in peripheral blood and infiltrate various organs throughout the body. Kiyoshi 
Takatsuki of Kumamoto University in Japan and Taku Uchiyama of Kyoto 
University collected samples. In 1981, Hinuma identified HTLV-1 to be the causative 
virus of ATL; this was the first report on tumor-induced retrovirus in humans. Most 
infected cells are CD4 + CD25 + T cells. Viral receptors are thought to involve other 
proteins and heparan sulfate. HTLV-1 is an approximately spherical virus particle 
about 100 nm in diameter and has an envelope. It has an RNA genome composed 
of the genes common to retroviruses such as gag, pro, pol, and env, as well as the 
gene encoding pX. It selectively uses the splicing and translation initiation sites in 
a region less than 2 kb called pX located between the env gene and the 3′ LTR [35] 
and uses the plus and minus strands relative to the transcription direction and effi-
ciently. It often encodes several regulatory and accessory genes. As described later, 
this pX is involved in the action of HTLV-1 encoding HTLV-1 bZIP factor (HBZ).
Tax and HBZ may be the carcinogenic potentials of HTLV-1. Tax is a potent 
transactivator essential for the activation of the viral promoter 5′ LTR. After enter-
ing the cell by infection, the virus particle capsid is lost, and the HTLV-1 genomic 
RNA is reverse transcribed to form genomic duplex DNA. Thereafter, the integrase 
encoded by the viral genome and the DNA end forms a complex, which contacts 
the genomic DNA on the cell side, and inserts by catalytic reaction. The 5-base-long 
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sequence of the targeted host cell genome is duplicated at both ends of the inserted 
viral genome in the insertion process. Tax, the transcript of TLV-1 regulatory gene 
tax, not only binds to the HTLV-1 promoter to promote viral transcription and 
expression but also interacts with cell-side transcription factors to activate host gene 
transcription activity. Therefore, tax is implicated in the early stages of tumori-
genesis of infected cells. However, in peripheral blood of most ATL patients, Tax is 
suppressed by its promoter 5′ LTR deletion and epigenetic modification. Thus, Tax 
is not essential, at least at the final stage of carcinogenesis. Recently, Matsuoka has 
suggested that Tax is constitutively expressed in a small fraction of leukemia cells, 
and this fraction triggers an anti-apoptotic mechanism to establish sustained infec-
tion and induces oncogenesis [36]. Tax is induced by a variety of cytotoxic stresses 
and also promotes HTLV-1 replication. Thus, it protects infected cells from apopto-
sis and increases the chance of viral infection at the critical phase of disease in the 
carrier. Another HBZ gene is expressed in all ATL patients causing and promoting 
the growth of ATL cells; therefore, it may be the gene responsible for ATL.
4.2 Insertion site of HTLV-1
At present, in addition to the carcinogenesis by the proteins of these viruses 
themselves, attention has been focused on the activation of host genes at the inser-
tion site. The integrated HTLV-1 provirus has the LTR [35] in both directions for 
the transcription. This sequence has many motifs that bind to transcription factors 
on the host and have strong promoter/enhancer activities. Therefore, there may 
be an increase in constitutive expression of the gene at the insertion site. Ogawa 
performed systematic genome analysis of ATL cells in 426 ATL patients and showed 
that genes interacting with Tax, T-cell receptor-NF-κB signal transduction, T-cell 
transport, and other T-cell-related pathways as well as genes related to immune 
surveillance are injured by the integration. Also, the expressions of VAV1, IRF4, 
and FYN related to lymphocyte maturation and signal transduction, chemokine 
receptors CCR4 and CCR7, and gene fusions (CTLA4-CD28 and ICOS-CD28) were 
enhanced in the infected cells [37]. Viral transcripts were mainly derived from 
the antisense strand. Also, the suppression of Tax expression and the constitutive 
expression of HBZ were observed in almost all patients. These insertion sites have 
not been known to be likely to occur in any particular sequence motif.
4.3 Clinical test for HTLV-1 detection
To date, no chromosomal abnormality specific to HTLV-1 has been observed, 
and Southern blot or inverse PCR methods are used for diagnosis; however, in 
recent years, multiplex LAMP (RT-LAMP) using universal probe has been devel-
oped. The method detects both HIV and HTLV-1 RNA from the same sample [39]. 
HAS HTLV-1 analyzing system (HAS)-Flow method has also been proposed to 
evaluate the progression of ATL stage by applying flow cytometric analysis focusing 
on surface markers of infected immune cells [38].
5. Integration model in mice lymphomas
5.1 The specificity of insertion sequence of the retrovirus genome
As experimental models of MLV integration, BXH2 [40], AKXD [41–44], and 
SL/Kh [20, 45–52] are well-known mouse strains into which endogenous provirus 
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genomes have been inserted. The genome of an endogenous MLV, AKV [14], was 
integrated into gltscr 1 [20], which has been characterized as a tumor suppressor 
gene. This locus was identified as emv11 on chr 7. In our previous work, the inserted 
AKV genome was shown to contain the full-length MLV genome and expressed to 
form a retroviral particle, which had the ability to infect lymphocytes according 
to its retroviral tropism. In the consequent tumorigenesis, the phenotype of the 
murine tumor is generally variable in inbred strains. For example, AKR/J mice are 
susceptible to T-cell lymphoma/leukemia [53–55]; however, in BXH2 mice [39, 40], 
tumors resemble myeloid and lymphocytic tumors. Even if the MLV is integrated 
into identical genes, the tumor phenotypes are variable [56]. It is likely that the 
individual genetic backgrounds of the inbred mouse strains determine the pheno-
type in combination with the integration-induced expression of oncogenes. Thus, 
oncogenes are responsible for the tumorigenesis; however, the phenotypes of the 
tumors are determined by other elements, including the genetic background. The 
insertion site of MLV has been studied using model mouse strains. SL/Kh strain is 
known to be a model of acute lymphocytic leukemia/lymphoma by MLV infection, 
and the target sequence of integration has been identified. This phenomenon may 
not always be generalized in human retroviruses as MLV LTR is very long and has 
palindromic motifs unlike HTLV-1 LTR. This sequence motif may contribute to the 
stabilization of the structure as the tetrameric integrase binds to the LTR. Such a 
stabilizing structure is not found in HTLV-1, and the retroviral genome may differ 
in HTLV-1 and MLV in this regard. The existence of a specific sequence motif in the 
genome insertion of the virus has been the subject of much debate and was initially 
resolved negatively in early days. The conclusion was that a virus integration is a 
random event [57] (by Howard Temin, who discovered reverse transcriptase and 
won the Nobel Prize in 1975). The randomness was proved through the genome 
analysis of infecting fibroblasts with integrated MLV in the culture state artificially. 
No common sequence motif for the insertion site was found in this way. However, 
there has been a report that active transcriptional genes can be the target of integra-
tion [21]. Besides, there are reports stating that palindrome sequence is favored by 
integration [16, 58]; however, the target sequence itself is yet to be identified. The 
idea is that viral insertion affects the transcriptional activity of the host cell genome 
by the three-dimensional structure of chromatin. A model may be considered in 
which the integrase complex binds to the site where DNA is locally released during 
transcription.
To study MLV genome insertion in vivo, inbred strains of mice harboring many 
copies of endogenous MLV genomes were developed. SL/Kh is one of the inbred strains 
(Tsukuba, Japan; http://www.riken.jp/engn/index.html) [14, 45]. In this strain, the 
harbored MLV genome is spontaneously and selectively integrated into the genome 
of the B-cell genome DNA. In reference to the data about MLV insertion sites in the 
genome of SL/Kh mice, whether MLV insertion occurred preferentially into the specific 
sequence motifs in the host cell genome was investigated. Stat5a [20, 51, 59, 60] and 
c-myc [47] were the target genes for MLV insertion. More than 95% studied SL/Kh mice 
had such the MLV genome (AKV) insertion in zinc finger protein 521 gene (Zfp521) in 
the genomic DNA of B-cell lineage at 7 weeks of age [61] (Figure 2).
5.2 Integration target sequence
To date, such significantly selective insertion into the specific gene has not been 
known. When insertion further occurs in an oncogene (e.g., Stat5a [51] or c-myc 
[47]) in addition to Zfp521 in the genome of SL/Kh mice, B lymphocytic leukemia 
develops.
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In AKXD and SL/Kh lymphoma genome, Zfp521 is one of the most frequent 
targets of MLV integration [62]. This gene locus was first reported as a common 
integration site, ecotropic retrovirus integration site 3 (Evi3) [61–64]. In more than 
400 male SL/Kh mice, >90% pre-B-lymphoma genomes acquired the integrated 
proviral genome within a 50-bp segment located in the region of the second to 
third exon of Zfp521. This target gene carries alternating palindrome sequences 
[16], which was frequently targeted by MLV insertion. Zfp521 is one the novel 
identified target genes. It probably contributes to chondrocyte development [65], 
in addition to B-cell development that requires an abnormal chimeric gene [64]. 
Each insertion occurs once or twice during the development of lymphoma within 
a 50-bp segment located in the second intron to the third exon of Zfp521. Most 
commonly, the insertion occurs at the “:” site in the sequence “CTGAATTGAAAC: 
AACTTCAGCTGTTT,” where the pair of underlined sequences and the pair of 
sequences in italics are palindromic sequences [61–63, 66]. The insertion does not 
occur randomly; they frequently occur at approximately 10-bp intervals and are 
symmetrically distributed within the shown 50-bp segment (Figure 3).
SL/Kh mouse has multiple copies of the endogenous virus, which produces viral 
particles and infects immature B-cell lineages suitable for tropism. Several common 
insertion sites such as Stat5a and Stat5b and well-known genes such as c-myc have 
been identified till date. Interestingly, many of these insertions occur upstream of 
the translational initiation site of the protein, so that many intact targeted proteins 
are produced. The fact that many insertions occur in such specific genes suggests 
that DNA structures such as palindromic sequences are targeted. However, insertions 
in a short 50-bp segment cannot have such secondary structure. MLV insertion was 
observed in almost the entire genome of this SL/Kh acute lymphocytic leukemia/lym-
phoma. The integration target segment is located just before the translation initiation 
Figure 2. 
Murine leukemia retrovirus (MLV) integration into oncogenes in SL/Kh lymphoma. In most cases of 
lymphoma, MLV integrations into more than one oncogenes, including Stat5a, c-myc, Fiz1, Hipk2, and others, 
are observed. It is not clear why the tumor cells are restricted to pre-B lymphoma phenotype. To date, genetic 
background dependent on Bomb1 is critical for conferring the phenotype. In addition, Stat5a and Zfp521 genes 
cooperate with IL-7 and pre-B cell receptor signal pathways, respectively. Host cell phenotype at the integration 
may contribute to the phenotypes. Differentiation stage of the host cell at the mutagenesis may be one of the 
critical factors of the phenotype.
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origin of the Zfp521 gene, which was first reported as a retrovirus insertion sequence. 
As a result of the insertion, downstream Zfp521 gene is constitutively expressed, and 
the upregulation may be responsible for acute lymphocytic leukemia/lymphoma.
5.3  Interaction partners for MLV integrase and recent developments in the 
biosafety of gene therapy
Recently, several cellular proteins including transcription regulatory factors 
and chromatin and RNA-binding proteins have been discovered as potential 
interaction partners for MLV integrase [67]. The bromodomain and extra-terminal 
domain (BET)-containing family of proteins (BRD2, BRD3, BRD4, and BRDT) act 
as cellular-binding partners of MLV integrase and preferentially bind to open chro-
matin regions that are enriched for transcription start sites, CpG islands, DNase 
I-hypersensitive sites, and proto-oncogenes [68–73]. The BET family of proteins 
plays a critical role in regulating gene transcription through epigenetic interactions 
between dual bromodomains and acetylated lysines on histones H3 and H4 during 
cellular proliferation, cell cycle progression, and differentiation processes [8, 9]. 
In vitro interaction analysis in human cells revealed that the ET domain of BRDs, 
BRD4 in particular, interacts with a motif in the unstructured C-terminal tail of 
MLV integrase, and these interactions are crucial for the recruitment of the MLV 
PIC to host DNA during integration [10, 11]. Through the recognition of open 
chromatin structure, BET proteins have been suggested to contribute to the tether-
ing of the MLV PIC to the host chromatin [10, 12]. Furthermore, it has been shown 
that the cell-permeable small molecule JQ-1, a pan-BET bromodomain inhibitor, 
prevents the BRD4-acetylated lysine interaction by competitively binding to BRD4 
and reduces MLV integration frequencies at transcription start sites [4, 13, 14]. 
These findings suggest that BET proteins navigate the MLV genome and promote 
efficient MLV integration around transcription start sites associated with a chro-
matin structure characteristic of an open, transcriptionally active domain [3].
The dual bromodomain protein of BRD2 promotes B-cell expansion and plays 
a critical role in the regulation of mitogenic response genes, particularly cyclin A, 
in B cells [15]. In addition, it has been shown that the inhibition of BRD4 leads to 
the suppression of germinal center B-cell differentiation and antibody responses 
through the down-regulation of nuclear factor-κBp65 activation and B-cell lym-
phoma 6 expression [16]. Hence, these BET proteins might broadly contribute 
to tumorigenesis in cooperation with MLV integration in spontaneous B-cell 
lymphoma development, and these findings likely provide novel standpoints of 
proto-oncogene function as well as a better understanding of MLV insertional 
mutagenesis [15, 17].
Figure 3. 
Alternate palindrome sequence in Zfp521. The upper and lower sequences represent the native sequence of host 
murine Zfp521 gene and the junction sequence of host murine Zfp521 gene with the integrated MLV genome, 
respectively. Green and red letters represent pairs of alternating palindromes. The sequences in the same colors 
are palindromes. The downward arrows represent the hot spot of the MLV integration.
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The stable integration of retroviral vectors is suitable to deliver therapeutic 
genes into cells to correct genetic diseases. MLV-based retroviral vectors are one of 
the most frequently used gene delivery vehicles in gene therapy studies for primary 
immunodeficiencies such as adenosine deaminase deficiency-severe combined 
immunodeficiency [10, 18, 19]. However, a subset of patients developed serious 
adverse events including leukemia that could be attributed to the integration 
pattern and vector design [10, 18]. MLV-based retroviral vectors integrate in the 
vicinity of transcription start site through the interaction between the C-terminal 
tail of MLV integrase (amino acids 381–408) and the ET domain of BET family 
of proteins [18, 20]. To resolve side effects such as leukemia, BET-independent 
MLV vectors have been developed by truncation of the C-terminal tail of MLV 
integrase or the single W390A mutation [18, 20]. Most recently, next-generation 
BET-independent MLV vectors have been engineered with the addition of the 
chromodomain of Chromobox protein homolog 1 (CBX1) to MLV integrase_W390A. 
The MLV integrase_W390A-CBX1 efficiently targets integration away from traditional 
markers of MLV integration including gene regulatory elements [10]. These find-
ings open new avenues to improve the biosafety of gammaretroviral vectors for 
gene therapy.
6. Summary
We followed the history of viral carcinogenic research in this review. The topic 
of viral carcinogenesis mentioned here is a case where the viral genome is inserted 
into the host genome. Because the molecular mechanism of viral carcinogenesis 
has been elucidated, significant novel technical methods will be developed in the 
future.
Clinical sequence analyzes gene changes occurring at diseased sites and provides 
information useful for diagnosis and treatment of diseases based on the results of 
gene mutations.
In addition to the various nucleic acid analysis methods such as conventional 
PCR and LAMP, next-generation sequencing and other rapid technological innova-
tion will aid in the measurement and analysis of numerous gene sequences in a 
short period. Furthermore, these technologies are expected to be used in the future 
to analyze infectious diseases such as cancer virus types, HPV high-risk groups, and 
virus insertion sites. Information on cancer virus infection will also be valuable for 
designing personalized drugs for cancer patients in the future.
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